objectives To estimate the magnitude of mortality and loss to follow-up and describe predictors of mortality among HIV-infected children in Guinea-Bissau.
Introduction
An estimated 1.8 million children under 15 years of age were living with HIV at the end of 2015. In that same year, 150 000 children became infected with HIV and 110 000 children died of AIDS [1] . In 2015, WHO revised its guidelines to recommend initiating treatment in all people diagnosed with HIV regardless of clinical stage or CD4 cell count. Therefore, all children diagnosed with HIV should be offered treatment. Even though access to treatment has improved, only 49% of HIVinfected children are estimated to have access. Without treatment, half of all children born with HIV will die by 2 years of age [1] .
Despite the high risk of early mortality without treatment, the average age at initiation of anti-retroviral treatment (ART) in resource-limited settings remains high [2] . WHO recommends that infants exposed to HIV are tested only a few weeks after birth [3] . Identifying HIVpositive infants using the common antibody HIV-test is challenging due to the presence of maternal HIV antibodies, which may persist for up to 18 months in the child's blood. Therefore, virologic testing is necessary to detect early HIV-infection in infants infected in utero or during birth [1] . As HIV-infected children have more rapid HIV disease progression than HIV-infected adults [4] , it is even more important for children to be diagnosed and start treatment early.
In Guinea-Bissau we previously found a high rate of loss to follow-up (LTFU) and mortality among HIVinfected adults [5, 6] . Also, virological testing was a The Bissau HIV Cohort Study Group details are given in Acknowledgements section. unavailable in Bissau until January 2017, so until then children were only tested at 18 months of age, potentially resulting in late diagnosis of HIV-infected children and a high rate of LTFU similar to that of adults [7] . However, no studies had examined this. Thus we aimed to estimate mortality, LTFU and predictors of mortality among HIVinfected children in Guinea-Bissau.
Methods

Setting and study population
This follow-up study was carried out at Hospital Nacional Simão Mendes (HNSM) between 2006 and 2016. HNSM is in the capital city of Bissau and houses the largest ART centre in Guinea-Bissau. The hospital provides care for citizens of Bissau but is also a reference centre for the other HIV-clinics in the country. Because of a shortage of staff, the care of children infected with HIV was moved from the paediatric ward to the adult HIVclinic at HNSM in September 2016.
Children are referred to HNSM from the largest HIVclinic for pregnant women in Bissau (C eu e Terras) or from other health centres if they test positive for HIV or present with clinical symptoms of HIV. At C eu e Terras, children are routinely tested for HIV at 18 months of age. HNSM is one of two clinics in Bissau that offers treatment for children with HIV. All children aged <15 years who were diagnosed with HIV at HNSM between February 20, 2006 , and September 30, 2016, were included. Thus, children who had already started treatment with ART at another clinic were not included. At the first visit, children were tested for HIV and demographic information was collected. Blood samples were usually drawn the following day. HIV-infected children were asked to come for control visits every 1-3 months and for a CD4 cell count every 3-6 months [8] . The guidelines for ART initiation for children in Bissau changed during the study period. From 2015 onward, all children diagnosed with HIV were recommended to initiate ART regardless of CD4 cell count. Prior to 2015, only children with a CD4 cell count <500 cells/ll were recommended to initiate ART.
HIV diagnostics
HIV screening of children older than 18 months was carried out using the rapid test Determine HIV-1/2 assay (Abbott Laboratories, Illinois, USA). Different types of confirmatory tests were used to discriminate between HIV-types, including SD Bioline HIV 1/2 3.0 (Standard Diagnostics, Inc., Kyonggi-do, South Korea), First [3] . Underweight was defined as weight-for-age Z-score ≤À2 for children <10 years of age and BMI-for-age Zscore ≤À2 for children ≥10 years of age [9] [10] [11] .
Severe anaemia was defined as having a haemoglobin level <70 g/l for children between 6 month and 5 years of age and <80 g/l for children 5-14 years of age [12] .
Baseline data included CD4 cell count, weight, BMI and haemoglobin measured within 3 months from the first visit to the clinic.
Statistical analysis
Cox-proportional hazards model was used to identify baseline characteristics associated with death or LTFU. Variables associated with death or LTFU in the univariable analysis (P < 0.10) were fitted to the multivariable analysis. Kaplan-Meier estimates of retention and mortality were determined. Missing data were included in the analyses in missing-data groups to avoid exclusion of patients. Patients who died or were transferred to another HIV-clinic were censored the date they died or were transferred. Patients lost to follow-up were censored at the date of their last visit to the clinic. The remaining patients were censored on October 1, 2016. Follow-up continued after the children turned 15 years old; thus, children were not able to age out of the cohort. Patients who had only been at the clinic on the day of HIV testing were considered to have 1 day of follow-up in order to include all patients in the calculation of HR for mortality and LTFU. Stata IC 13.0 (StataCorp, College Station Texas, USA) was used for statistical analyses.
Ethical considerations
Written information was given in the official language Portuguese and oral information in the widely spoken Portuguese Creole. Informed written consent, or a fingerprint if illiterate, was provided by the child and his/her parent/guardian. The Bissau HIV cohort was approved by the National Ethics Committee in Guinea-Bissau (No.
Ref. 070/CNES/INASA/2017).
Results
Baseline characteristics
Between February 20, 2006 , and September 30, 2016, 548 children under 15 years of age attended the HIVclinic at HNSM. Of these children, 23 had received ART elsewhere. The remaining 525 children were diagnosed with HIV at HNSM, or at another HIV-clinic and transferred to HNSM before ART initiation, and included in the study. The number of children diagnosed with HIV at HNSM has been increasing (P < 0.01; Figure 1 ).
The baseline characteristics of the 525 children diagnosed with HIV are given in Table 1 . The median age at diagnosis was 3.5 years (IQR 1.6-7.9 years) and 170 (32.4%) were below 2 years of age at diagnosis. Within the first 90 days after HIV diagnosis, 311 children (59.2%) had a CD4 cell count measurement, 179 children (34.1%) had a haemoglobin measurement, and 192 children (36.6%) had weight or BMI measured. The median CD4 cell count at diagnosis was 382 cells/ll (IQR 141-847). Among children with a CD4 cell count measured at diagnosis, severe immunodeficiency was found in 139 (44.7%). 114 (59.4%) of the children with weight or BMI available at diagnosis were underweight. 22 (12.3%) of children with haemoglobin measured at diagnosis had severe anaemia (Table 1) .
ART
During the study period, 386 (73.5%) children initiated ART. The median age at ART initiation was 4 years (IQR 2-9). Within the first month after diagnosis, 309 (58.9%) of all children had initiated ART (Table 2) . Year of diagnosis 
Mortality and LTFU
By
One-year outcome
A total of 454 patients were diagnosed with HIV before October 01, 2015; thus, it was possible to evaluate a 1-year outcome for these children. Within the first year of follow-up, 11.0% children died, 3.1% were transferred, and 38.8% became lost to follow-up, leaving 47.1% in follow-up ( Figure 2 ). For children with a 1-year outcome, 187 (41.2%) deaths or losses to follow-up (attrition) occurred within the first 3 months, 204 (44.9%) within the first 6 months and 226 (49.8%) within the first year.
Univariable assessment of mortality risk
Severe immunodeficiency (HR = 2.32, 95% CI: 1.29-4.17) and underweight (HR = 2.79, 95% CI: 1.40-5.55) at diagnosis were predictors of mortality (Table 3) . Kaplan Meier curves for time to death after diagnosis stratified by severe immunodeficiency and underweight at diagnosis are shown in Figure 3 . Children in the age groups 2-5 years (HR = 0.30, 95% CI: 0.13-0.70) and 5-10 years (HR = 0.41, 95% CI: 0.19-0.92) at diagnosis had a lower mortality rate than children under 1 year of age. Children with unknown immunodeficiency status and unknown HIV-type at diagnosis had a higher mortality rate than children with no severe immunodeficiency and HIV-1, respectively. There was a tendency for children with unknown anaemia status at diagnosis to have a higher risk of dying compared to children with no severe anaemia. Comparing children with unknown data on immunodeficiency and HIV-type at diagnosis with children who had data for these variables revealed an association between a lack of data and death for children with unknown immunodeficiency status (HR = 1.56, 95% CI: 1.00-2.43) and unknown HIV-type (HR = 2.13, 95% CI: 1.26-3.60).
Multivariable assessment of mortality risk
Severe immunodeficiency (aHR = 2.52, 95% CI: 1.22-5.21) and underweight (aHR = 3.14, 95% CI: 1.40-7.02) at diagnosis remained predictors of mortality in the multivariate analysis.
Children in the age group 2-5 years (aHR = 0.29, 95% CI: 0.11-0.74) at diagnosis also had a lower mortality rate in the multivariable analysis, whereas children aged 5-10 years (aHR = 0.46, 95% CI: 0.18-1.15) at diagnosis had a tendency for lower mortality than children under 1 year of age at diagnosis. Unknown HIVtype and unknown immunodeficiency status at diagnosis was associated with death.
Sensitivity analysis
To determine the impact of LTFU a sensitivity analysis was performed. In this analysis, we investigated predictors of attrition (children dead or lost to follow-up) in order to assess the impact of assuming all children lost to follow-up were dead.
Besides unknown HIV-type and unknown immunodeficiency status, underweight (aHR = 1.79, 95% CI: 1.20-2.67) at diagnosis was the only significant predictor of attrition. Children aged 1-2 years (aHR = 0.69, 95% CI: 0.46-1.03), 2-5 years (aHR = 0.68, 95% CI: 0.45-1.01), and 5-10 years (aHR = 0.52, 95% CI: 0.34-0.81) at diagnosis had a lower attrition rate than children under 1 year of age at diagnosis, though not all were significant. Children with mothers who died before diagnosis also tended to have a slightly lower attrition rate (aHR = 0.67, 95% CI: 0.45-1.00) ( Table 3) .
Discussion
This retrospective follow-up study examined the outcome of all children diagnosed with HIV at the largest HIVclinic in Guinea-Bissau. Half of the children had died or been lost to follow-up one year after diagnosis. At the end of the study period, only one-third of the children were still in follow-up. Severe immunodeficiency, underweight, young age at diagnosis, and unknown CD4 cell count or HIV-type were predictors of mortality. In addition to the long follow-up period, a main strength of this study was that it describes a setting in which resources are very limited. Cohorts with resources for retaining patients may also have more resources to publish, causing publication bias with an underestimation of attrition. Active follow-up was limited to calling patients or a contact person by telephone, which is often the only active follow-up possible in resource-limited settings. The sub-Saharan setting makes it possible to use Attrition is the combined cumulative incidence of death or loss to follow-up; HIV, human immunodeficiency virus; BMI, body mass index; PMTCT, prevention of mother-to-child transmission; HR, hazard ratio; aHR, adjusted hazard ratio.
our results to improve the care of children living with HIV not only in Bissau but also elsewhere in subSaharan Africa. However, the setting also causes our study to be limited by incomplete data for many key variables that may have affected the outcome estimates in either direction. This study showed that the number of children diagnosed with HIV at HNSM is increasing. We would have expected the opposite because ART has been available for prevention of mother-to-child transmission (PMTCT) for 14 years. Furthermore, studies from Guinea-Bissau have shown that the number of people infected with HIV has been steady or maybe even declining over the last 10 years among both the general population [13] and pregnant women [14] . The rise in children diagnosed with HIV may be explained by better diagnostics or a higher rate of referral to HNSM from other health care centres.
In accordance with other studies from sub-Saharan Africa [15] [16] [17] [18] , this study showed a high median age at diagnosis. We do not know if the children were infected at birth, shortly after birth due to breastfeeding, or later in life. It is possible that some children were infected after blood transfusion, which was described previously in a survey from Guinea-Bissau [19] . Importantly, 44.7% of children with a CD4 cell count were immunosuppressed at baseline, indicating that the high median age can not only be explained by high age at infection, but is also a sign of late diagnosis, as is common in Bissau [7] . This finding is disturbing, as HIV disease progression is especially rapid in children, and a low nadir CD4 cell count causes permanent damage to the children's immune system and treatment should be started early. The late diagnosis suggests that a relatively large proportion of HIV-infected children in Bissau die before diagnosis.
One of the reasons for the late diagnosis in Guinea-Bissau is the lack of virologic testing until recently, which meant that children could only be tested for HIV at 18 months of age. The lack of virologic testing can also explain the higher mortality among the youngest children compared to children of an older age (<1 vs. 2-5 years), which has also been described in other studies [17, 18, 20, 21] . Because of the lack of routine virologic testing of children born to HIV-infected women, children under 18 months of age are only diagnosed with HIV if they show symptoms. Therefore, the group of children under 1 year of age will only include children sick enough to show symptoms, whereas the group of children between 2 and 5 years of age will contain both children with symptoms and children without symptoms diagnosed with a routine antibody test after 18 months of age.
The national HIV program in Guinea-Bissau recommends that all pregnant HIV-infected women receive ART and HIV-exposed infants receive postpartum ART prophylaxis. Children born to women infected with HIV-1 should receive nevirapine (NVP) whereas children born to women infected with HIV-2 or HIV-1/2 should receive zidovudine for 45 days. The staff at the largest HIVclinic for pregnant women in Bissau aim to follow the above-mentioned recommendations for PMTCT, but we do not have access to data on how many of the HIVexposed infants actually receive the prophylaxis and how many mother-to-child transmissions are averted. Our data reveal that PMTCT is not effective in every case, as 49 (9.3%) children were infected despite initiating PMTCT. Similar to what was shown in Malawi [22] , it is likely that children who do not finish the PMTCT program are less likely to be tested for HIV, resulting in an underestimation of how often initiated PMTCT fails. program failure. To improve PMTCT coverage and effectiveness, strategies that improve HIV and PMTCT knowledge and more effective counselling are needed [23] . When counselling it is important to address stigma and take local cultural beliefs into account. Furthermore, test shortages during periods of political instability is likely a contributing factor to PMTCT-program failure [24] and may be avoided by having larger national stocks. With approximately 7000 deliveries annually at HNSM and an HIV prevalence of 5.1% among pregnant women in Guinea-Bissau [24] , 525 inclusions over a 10-year period may be an underestimation of the actual number of HIV-infected children. To estimate the proportion of HIV-infected children that never reach health care, we would need data on the effectiveness of PMTCT and a better overview of how many children receive care outside HNSM.
In the newest WHO guidelines on ART, children should be treated with a protease inhibitor instead of a non-nucleoside reverse transcriptase inhibitors (NNRTI) [25] . In this study, most children were treated with the NNRTI nevirapine. There is a high proportion of NNRTI resistance in Guinea-Bissau [26] , which can be transmitted to the children if the mothers have poor adherence to ART. Therefore, it is especially important that the children in Guinea-Bissau receive a protease inhibitor. Also, children with HIV-2 should receive a protease inhibitor because NNRTI is not effective against HIV-2.
The attrition rate in this study was very high. The 1-year mortality of 11.0% seems to be comparable to what has been reported previously in studies from Africa (6.0-11.0%) [2, 15, 17, 27, 28] , but the rate of LTFU appears to be much higher than in other African studies [16, 17, 28, 29] , though comparison are difficult because of different definitions of LTFU. A higher rate of LTFU in Guinea-Bissau compared to other African studies has also been found among adults [5] .
In this study, mortality estimates represent only documented mortality. For some children lost to follow-up the cause is probably death. Furthermore, children lost to follow-up will evidently die if they do not receive treatment. Therefore, we expect that the true mortality rate was higher than presented here. In a study on LTFU among adult HIV-infected patients from Guinea-Bissau, one-third of the traced patients had died. Frequent reasons for LTFU among traced and living adult patients were moving, travelling, and transfer [30] . Furthermore, frequent periods of political instability resulting in a shutdown of the HIVclinic at HNSM and the national laboratory have led to treatment interruptions and likely LTFU [24] .
Deaths and LTFU happened very early after diagnosis, which corroborates the findings of several other studies [15, 17, 27] . Severe immunosuppression based on CD4 cell count [2, 15, 17, 18, 20, [27] [28] [29] 31] , underweight [17, 27, 29, 32] , and anaemia [2, 15, 17, 27, 29] are supported as predictors of mortality by studies from subSaharan Africa.
A substantial proportion of the children were diagnosed with HIV-1/2 dual infection, which is not in accordance with former studies of HIV-1/2 prevalence in the general population [13] and among pregnant women [14] from Guinea-Bissau. Furthermore, the high number of HIV-1/2 dual infections is not consistent with the rare vertical transmission of HIV-2 [33] . During the study period, different discriminatory HIV tests have been used in Guinea-Bissau, including SD Bioline HIV 1/2 3.0. Another study from Guinea-Bissau found that this test may overestimate the number of patients dually infected with HIV-1/2 [34, 35] .
Missing data on immunodeficiency and HIV-type were significantly associated with death, and there was a tendency for an association between death and missing data on anaemia. This finding could indicate that children with no blood sample drawn for CD4 cell count, haemoglobin, or HIV-type discrimination had a higher mortality rate. It is possible that very sick children had blood drawn less frequently because they are more difficult to draw blood from or because they died before blood sampling. In another study, lack of immunological status was shown to be the biggest risk factor for mortality [18] , whereas yet another study found no association with mortality [32] .
The standard of follow-up in Bissau may be worse than what was shown in this study. Children are only categorised as lost to follow-up if their last visit was more than 6 months before the date of closure of the database. Many children categorised as under follow-up had been absent from the clinic for many months or even years but eventually returned to the clinic. Thus, these children have been lacking medicine for longer periods of time. Further studies describing time on follow-up without regular consultations and access to medicine are needed to better understand the quality of follow-up among children in Bissau.
The conditions at HNSM may not be representative of the whole country because HNSM is located in the capital. To understand the general conditions for HIVinfected children nationwide, data from more clinics are needed.
Conclusions
In Guinea-Bissau, the rates of early mortality and LTFU among HIV-infected children were disturbingly high. The children were relatively old when diagnosed with HIV. Markers of advanced disease at diagnosis, such as severe immunodeficiency and underweight, were predictive of mortality. Initiatives to ensure more effective PMTCT, early diagnosis and better retention are urgently needed.
